CINECA IRIS Institutional Research Information System

NUTI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.264
AS - Asia 6.864
EU - Europa 4.286
SA - Sud America 798
AF - Africa 228
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 23.455
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.901
HK - Hong Kong 1.987
SG - Singapore 1.860
CN - Cina 1.586
IT - Italia 1.487
BR - Brasile 653
DE - Germania 557
SE - Svezia 535
VN - Vietnam 444
BG - Bulgaria 362
GB - Regno Unito 300
FR - Francia 283
TR - Turchia 262
CA - Canada 255
FI - Finlandia 198
IN - India 184
RU - Federazione Russa 147
JP - Giappone 131
UA - Ucraina 117
SN - Senegal 67
BD - Bangladesh 63
AR - Argentina 56
ES - Italia 56
MX - Messico 51
IQ - Iraq 49
AT - Austria 48
KR - Corea 48
CH - Svizzera 41
ZA - Sudafrica 36
ID - Indonesia 34
PK - Pakistan 34
NG - Nigeria 33
SA - Arabia Saudita 33
BE - Belgio 32
NL - Olanda 25
CO - Colombia 21
EC - Ecuador 20
PL - Polonia 18
VE - Venezuela 18
MA - Marocco 17
KE - Kenya 15
UZ - Uzbekistan 15
MY - Malesia 14
JM - Giamaica 13
TW - Taiwan 13
GR - Grecia 12
CI - Costa d'Avorio 11
CZ - Repubblica Ceca 11
DZ - Algeria 11
IE - Irlanda 10
TT - Trinidad e Tobago 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
IL - Israele 9
IR - Iran 9
KZ - Kazakistan 9
LT - Lituania 9
PH - Filippine 9
AZ - Azerbaigian 8
DK - Danimarca 8
PY - Paraguay 8
BO - Bolivia 7
CL - Cile 7
JO - Giordania 7
LB - Libano 7
TN - Tunisia 7
AU - Australia 6
ET - Etiopia 6
KG - Kirghizistan 6
NP - Nepal 6
PS - Palestinian Territory 6
UY - Uruguay 6
AL - Albania 5
BB - Barbados 5
CR - Costa Rica 5
BJ - Benin 4
HR - Croazia 4
PA - Panama 4
SY - Repubblica araba siriana 4
BH - Bahrain 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HU - Ungheria 3
NZ - Nuova Zelanda 3
OM - Oman 3
SV - El Salvador 3
TH - Thailandia 3
VI - Stati Uniti Isole Vergini 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
CG - Congo 2
EU - Europa 2
LV - Lettonia 2
ME - Montenegro 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
PR - Porto Rico 2
PT - Portogallo 2
Totale 23.425
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.970
Ashburn 1.113
Singapore 1.083
Woodbridge 1.068
Ann Arbor 910
Chandler 725
Houston 701
Fairfield 688
Santa Clara 569
San Jose 561
Dallas 510
Sofia 361
Shanghai 350
Beijing 341
Serra 332
Seattle 298
Milan 288
Wilmington 268
New York 256
Cambridge 219
Ottawa 191
Boardman 179
Los Angeles 173
Princeton 173
Izmir 163
Jacksonville 141
Lawrence 139
Council Bluffs 135
Nanjing 122
Medford 120
Florence 119
Lauterbourg 119
London 117
Tokyo 116
Des Moines 108
Ho Chi Minh City 103
Bremen 93
Hefei 80
Dong Ket 78
Frankfurt am Main 69
Pisa 69
Dakar 67
Istanbul 66
Hanoi 64
Helsinki 58
São Paulo 58
Redondo Beach 54
Munich 51
Buffalo 50
Marseille 41
Nanchang 41
Rome 40
Seoul 40
Vienna 38
Redwood City 37
Dearborn 35
Hebei 31
Lagos 31
Brussels 30
Columbus 30
Livorno 30
San Diego 30
Bern 29
Lucca 29
Ogden 28
Pune 27
The Dalles 27
Baghdad 26
Lancaster 26
Rio de Janeiro 26
Gif-sur-Yvette 25
Kunming 25
Changsha 24
Pessac 24
Boulder 23
Nürnberg 23
Chicago 22
Belo Horizonte 21
Guangzhou 21
Orem 20
Shenyang 20
Alessandria 19
San Francisco 19
Chennai 18
Da Nang 18
Johannesburg 18
Jüchen 18
Toronto 18
Turku 18
Jiaxing 17
Norwalk 17
Auburn Hills 16
Dhaka 16
Hangzhou 16
Nuremberg 16
Tianjin 16
Denver 15
Washington 15
Mexico City 14
Nairobi 14
Totale 16.924
Salva come PNG Salva come JPEG
Nome #
Strategies to target ADAM17 in disease: From its discovery to the iRhom revolution 1.275
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 258
Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies 226
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization 219
ADAMs and ADAMTs selective synthetic inhibitors 218
Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators 213
Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles 210
Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates 207
ADAM metalloproteinases as potential drug targets 205
Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide 202
INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE 200
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate-Benzenesulfonamide Conjugates 196
Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds 196
Age-related macular degeneration: Current knowledge of zinc metalloproteinases involvement 194
Ionic liquid-promoted green synthesis of biologically relevant diaryl thioethers 194
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors 192
Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors 192
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 191
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors 190
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity 188
A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer 188
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides 187
Synthesis of New Classes of MMPs Sugars-Based Inhibitors 185
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 184
Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models 184
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP) 183
Matrix metalloproteinase inhibitors prevent the release and proteolytic activity of monocyte/macrophage-derived microparticles 183
N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors 182
New bifunctional metalloproteinase inhibitors: an integrated approach towards biological improvements and cancer therapy. 182
Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-a Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models 180
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis 178
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. 178
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors 178
Drug design of sulfonylated MMP inhibitors 177
Synthetic analogs of xanthohumol for use in the prevention and​/or treatment of tumors 177
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 175
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs 172
Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives 171
Crystallization of bi-functional ligand protein complexes 171
Arylsulfonamide derivatives as metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 171
Aryl-sulphonamidic dimers as metalloproteases inhibitors 170
Immobilization of matrix metalloproteinase 8 (MMP-8) for online drug screening 170
Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition 169
Analysis of Human Carbonic Anhydrase II: Docking Reliability and Receptor-Based 3D-QSAR Study 169
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect 167
Compounds with a benzo [a]carbazole structure for use in the prevention and/or treatment of infectious diseases 165
Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors 165
In Vivo Imaging of Matrix Metalloproteinase 12 and Matrix Metalloproteinase 13 Activities in the Mouse Model of Collagen-Induced Arthritis 165
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs 164
Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues 163
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models 162
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors 161
Design of selective collagenase 3 (MMP-13) inhibitors as potential therapeutic agents in rheumatoid arthritis 160
MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions 159
Powerful twin carboxylic inhibitors for MMP homodimerization 156
Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity 156
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP 154
Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors 154
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 152
Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups 151
Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes 151
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma 150
Amino Acid Derivatives as New Zinc Binding Groups for the Design of Selective Matrix Metalloproteinase Inhibitors 150
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases 148
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors 147
1-(PHENYLSULPHONAMIDO)-PYRAZOLE DERIVATIVES AS CARBONIC ANHYDRASE INHIBITORS. 146
NMR STUDIES OF A NEW POTENT MMP-12 INHIBITOR: INSIGHT INTO KEY BINDING INTERACTIONS 144
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates 144
Arylsulfonamido compounds as metalloprotease inhibitors and their preparation, pharmaceutical compositions and use as diagnostic as well as radiotherapeutic agents 143
Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent MMP-12 inhibitors 142
Novel Peptidomimetic as MMP-2 Inhibitors 141
Identification of broad-spectrum mmp inhibitors by virtual screening 141
Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New 18F‑Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission Tomography 140
Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays 140
Synthetic MMP Inhibitors: Slow-Binding Behaviour of Enantioselective N-O-Sulfonamido Based Inhibitors Directed to Specific Matrixins 139
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 139
Design of Selective Collagenase 3 (MMP-13) Inhibitors as Potential Therapeutic Agents in Rheumatoid Arthritis 135
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NEW 7BETA-(BENZO[A]DIHYDROCARBAZOLYLOXYACETYL)-SUBSTITUTED CEPHALOSPORINS 135
A disintegrin and metalloproteinases (ADAMs) and tumor necrosis factor-alpha-converting enzyme (TACE) 134
Effects of selective MMP-2 inhibitors on viability and invasiveness in the U87MG human glioblastoma cell line 134
Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors 131
New chromane, thiocromane and tetrahydronaphtalene oxime ether derivatives combining SERT and a2-adrenoceptor affinity 131
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis 131
Design, Synthesis and Inhibitory Properties of Potent Sulfonyl Diaryl Based MMPs and TACE inhibitors 130
Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit a- and ß-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms 130
Analoghi sintetici dello xantumolo 130
Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors 130
Targeting ADAM17 Sheddase Activity in Cancer 130
Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies 129
New 18F-Labelled Inhibitors of Matrix Metalloproteinases as Imaging Probes for PET Imaging 128
D2 dopamine receptor agonists as allosteric modulators of A2A adenosine receptor signalling 126
A series of benzensulfonamide derivatives as new potent carbonic anhydrase IX and XII inhibitors 125
Molecular Underpinnings of MMP-13 Selective Inhibition by Arylsulfonamido Hydroxamate Analogues as Potential Therapeutic Agents in Osteoarthritis 125
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization 125
A new small molecule, D2 dopamine receptor agonist, as an allosteric modulator of A2A adenosine receptor signalling 125
Multivalent MMP-12 inhibitors as a valuable approach to counteract the intestinal epithelial barrier impairment and inflammation in an in vitro model mimicking intestinal high-fat exposure 124
Identification of N-Acyl Hydrazones as New Non-Zinc-Binding MMP-13 Inhibitors by Structure-Based Virtual Screening Studies and Chemical Optimization 124
Discovery of a new subnanomolar Tumor Necrosis Factor-alpha Converting Enzyme (TACE) inhibitor as antiinvasive agent 124
Arylsulfonamide derivatives, especially dimeric hydroxamic acid-​containing amino acids, metalloproteases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of degenerative disorders 124
Identification of a Novel p53 Modulator Endowed with Antitumoural and Antibacterial Activity through a Scaffold Repurposing Approach 123
Totale 17.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.590 30 179 34 63 287 218 46 74 49 40 85 485
2022/20232.238 251 270 147 283 236 266 13 166 403 11 151 41
2023/20241.466 163 137 149 93 192 292 72 69 24 33 112 130
2024/20254.481 27 180 95 260 460 402 419 247 431 569 424 967
2025/20266.666 407 1.855 650 426 557 481 880 246 370 458 194 142
2026/2027100 100 0 0 0 0 0 0 0 0 0 0 0
Totale 23.814